Title:
SUBSTITUTED BENZIMIDAZOLE COMPOUND AND COMPOSITION COMPRISING SAME
Document Type and Number:
WIPO Patent Application WO/2019/096112
Kind Code:
A1
Abstract:
Provided are a substituted benzimidazole compound, and a composition comprising same and use thereof. The substituted benzimidazole compound is a compound represented by formula (I), or a pharmaceutically acceptable salt, prodrug, hydrate or solvate compound, polymorph, stereoisomer, or isotopic variation thereof. The compound can be used for treating and/or preventing related diseases caused by MEK, such as hyperproliferative diseases, pancreatitis, kidney diseases, blastocyte implantation, and diseases related to vasculogenesis or angiogenesis.
Inventors:
WANG YIHAN (CN)
LIU ZHIQIANG (CN)
LIU ZHIQIANG (CN)
Application Number:
PCT/CN2018/115161
Publication Date:
May 23, 2019
Filing Date:
November 13, 2018
Export Citation:
Assignee:
SHENZHEN TARGETRX INC (CN)
International Classes:
C07D235/08; A61K31/4184; A61P35/00
Foreign References:
| CN1874768A | 2006-12-06 | |||
| CN101360718A | 2009-02-04 | |||
| CN1652792A | 2005-08-10 | |||
| CN104870427A | 2015-08-26 | |||
| CN103764134A | 2014-04-30 |
Other References:
BERGE ET AL.: "pharmaceutically acceptable salts in detail", J. PHARMACEUTICAL SCIENCES, vol. 66, 1977, pages 1 - 19
ADVANCED DRUG DELIVERY REVIEWS, vol. 19, 1996, pages 115
J. MED. CHEM., vol. 39, 1996, pages 10
See also references of EP 3712133A4
ADVANCED DRUG DELIVERY REVIEWS, vol. 19, 1996, pages 115
J. MED. CHEM., vol. 39, 1996, pages 10
See also references of EP 3712133A4
Download PDF: